Navigation Links
Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
Date:8/19/2009

monitored by the Sterling Institutional Review Board of Atlanta, Georgia. Support for the study was provided by Aton Pharma, Inc.

About Lacrisert

Lacrisert has been FDA-approved for use in patients with moderate to severe dry eye and available by prescription for more than two decades. Unlike artificial tear substitutes that have a residence time measured in minutes, Lacrisert provides continual lubrication and protection to the surface of the eye for all-day relief. Lacrisert acts to stabilize and thicken the pre-corneal tear film and prolong the tear film breakup time, which is usually accelerated in patients with dry eye states. Information and educational video content are available at www.Lacrisert.com.

Most adverse reactions with Lacrisert were mild and transient and included transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids and hyperemia. Lacrisert should not be used by patients who are hypersensitive to hydroxypropyl cellulose. If improperly placed, Lacrisert may result in corneal abrasion.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of ten products, with sales in over 30 countries, focuses on ophthalmic diseases, orphan conditions and acute care hospital products. For more information, see www.atonrx.com.

<
'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Accuray Incorporated (Nasdaq: ARAY ), a global ... that the first CyberKnife® Robotic Radiosurgery System in ... of Liege. ,, The University Hospital in ... largest hospitals in Euregio, a cross-country region of ... range of cancer treatments, University Hospital of Liege ...
(Date:12/14/2009)... Colo., Dec. 14 Manchester Pharmaceuticals, Inc.(TM) ... (chenodiol tablets). On October 22, 2009, the ... an important therapy for patients suffering from gallstones ... due to disease or advanced age. ,, Chenodal ... exclusively through Centric Health Resources ("Centric"), a specialty ...
(Date:12/14/2009)... Pf enex Inc. announced today that it has ... exclusive worldwide license to Pf enex Expression Technology(TM) ... production of specific proteins to be used ... ,, Under the terms of the agreement Pf ... upfront and milestone payments as well as additional royalty ...
Breaking Medicine Technology:First CyberKnife in Belgium to be Installed at Leading University Hospital 2First CyberKnife in Belgium to be Installed at Leading University Hospital 3Manchester Announces Availability of Chenodal(TM) 2Menopause Often Means Worsening Cholesterol 63117 1Menopause Often Means Worsening Cholesterol 63117 2Menopause Often Means Worsening Cholesterol 63117 3Bridgepoint Educations University of the Rockies Introduces New Master of Arts Specialization in Career Management and Counseling 63113 1Bridgepoint Educations University of the Rockies Introduces New Master of Arts Specialization in Career Management and Counseling 63113 2Rosalie Dunn Ph D Joins Gwathmey Inc as Chief Executive Officer 15148 1Rosalie Dunn Ph D Joins Gwathmey Inc as Chief Executive Officer 15148 2
... Surface Logix, Inc. today announced,that Jim Mahoney, President and ... drug development pipeline at the 19th Annual Piper,Jaffray Health ... Hotel in New York City. Mr. Mahoney,s presentation will ... EST., Surface Logix currently has two programs in ...
... SGP ) today announced that the U.S. ... for review of the New Drug,Application (NDA) for ... approval from the FDA for the treatment,of schizophrenia ... Bipolar I,Disorder. In accepting the NDA, the ...
Other Medicine Technology:Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 2Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 3Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA 4
(Date:12/14/2009)... of Tens of Thousands of New Chronic Hepatitis ... -- Legislation approved by Congress providing for federal ... helping to reduce tens of thousands of new ... United States, the National Viral Hepatitis Roundtable ... included in the FY 2010 Consolidated Appropriations bill ...
(Date:12/14/2009)... -- On December 9, 2009, the United States Court ... that private insurance companies are "plans" and therefore subject ... federal courts have held that contracts issued by insurance ... 18 Section 1347, US vs. Frost is ... held to be a "plan," because, as the government ...
(Date:12/14/2009)... could be linked to scans performed in 2007 , , ... are exposing patients to far more radiation than previously thought ... cancers a year, two new studies claim. , Based on ... Archives of Internal Medicine , the study authors, joined ... calling on clinicians to limit radiation exposure to patients. , ...
(Date:12/14/2009)... San Diego School of Medicine and Osaka University in ... liver damage, including inflammation, fibrosis and cancer. The findings ... TAK1, works could lead to new insights into the ... appears to be a master regulator of liver function," ... Dean of the UC San Diego School of Medicine. ...
(Date:12/14/2009)... asthma, COPD, researchers say , , MONDAY, Dec. 14 (HealthDay ... influence lung function, a finding that may help lead ... team of researchers compared lung function with genetic variants ... human genome in more than 20,000 people of European ... genetic variants associated with alterations in lung function. , ...
Breaking Medicine News(10 mins):Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Scientists uncover protective mechanism against liver cancer 2
... cardiovascular problems in elite-level football players should begin in ... and professional players. Mayo Clinic physicians based that conclusion ... cardiovascular health of 233 retired National Football League (NFL) ... percent of NFL players under age 50 had abnormal ...
... March 27 Dominion Diagnostics,LLC, the premier ... medication monitoring, and support services nationwide, today,announced ... The new site, http://www.dominiondiagnostics.com, is operational ... part of Dominion,s continuing initiative to provide ...
... American,Pharmaceutical Inc., the U.S. subsidiary of Japanese pharmaceutical,manufacturer ... more than,$4 million to resolve allegations that it ... the Justice Department announced,today., Otsuka developed Abilify ... Bristol-Myers Squibb (BMS) to co-promote sales of the ...
... 27 Hundreds of,determined members of SEIU United ... union headquarters (560 Thomas L. Berkley Way) Thursday ... by SEIU,s Washington,officials to subvert democracy, centralize power ... healthcare workers will declare their,intention to retain control ...
... CryoCor, Inc. (Nasdaq:,CRYO), reported today that its ... with a "going concern" qualification. The going-concern,qualification is ... expressing substantial doubt, based upon current financial,resources, as ... obligations,beyond 2008 without access to additional working capital. ...
... report finds, , , THURSDAY, March 27 (HealthDay News) -- Older ... and financial security, a new report finds. , Yet ... groups. , In 2006, there were an estimated 37 million ... By 2030, it,s estimated at 71.5 million people will be ...
Other Medicine News:Health News:Mayo Clinic finds retired NFL players at increased risk for heart problems 2Health News:Mayo Clinic finds retired NFL players at increased risk for heart problems 3Health News:Dominion Diagnostics Announces Launch of Comprehensive New Company Website 2Health News:Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify 2Health News:Hundreds of Workers Gather to Denounce Efforts to Thwart Union Democracy 2Health News:CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders' Equity 2Health News:CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders' Equity 3Health News:Most Older Americans Living Longer and Better 2Health News:Most Older Americans Living Longer and Better 3Health News:Most Older Americans Living Longer and Better 4
... FASTIN RC is a ... for rotator cuff procedures. The ... a small core to optimize ... independent suture channels to prevent ...
... 5mm Super Revo Suture Anchor offers a ... a mini-open rotator cuff repair. The cutting ... is pre-threaded with two #2 strands of ... suture management are avoided with the Independent ...
... 5mm Super Revo Suture Anchor offers a ... a mini-open rotator cuff repair. The cutting ... is pre-threaded with two #2 strands of ... suture management are avoided with the Independent ...
The Linvatec UltraFix Suture Anchor System's smooth surface until deployed eliminates tissue, bone and suture damage and its ultra smooth eyelet hole preserves suture integrity....
Medicine Products: